Patient Group

(N)

Sample Analyzed^*

Age in years (mean ± SD)

Metastatic Cancer

BMI

(mean ± SD)

HT^**

ER+ HT sensitive

5

4/5^*

66.6 ± 5.6

4/4

24.4 ± 3.5

multiple

ER+ HT resistant

2

2/2

65.0 ± 1.4

2/2

29.5 ± 2.1

multiple

ER− primary, metastatic

1

1/1

27

1/1

28.0

Neo-adjuvant

ER+ primary

4

2/4^*

56.8 ± 11.2

0/2

35.0 ± 14.1

None

Healthy controls

2

2/2

56.0 ± 5.7

0/2

26.5 ± 9.2

None